|Awarded On||February 18, 2015|
|Title||Personalized Cellular Immunotherapy against Novel Cancer Targets|
|Program||Product Development Research|
|Award Mechanism||New Company Product Development Award|
|Institution/Organization||Immatics US Inc.|
|Principal Investigator/Program Director||Walter Steffen|
|Cancer Sites||Brain and Other Nervous System, Pancreas|
Immatics GmbH (Germany) has been successfully developing off-the-shelf cancer immunotherapies for the past decade. Immatics US Inc. (Houston, Texas), a newly created subsidiary of Immatics GmbH, is a first-in-class biopharmaceutical company dedicated to the development of novel personalized cancer immunotherapies including (1) adoptive cellular therapy (ACT) and (2) actively personalized vaccines (APVACs). Both types of immunotherapies activate the patient’s immune cells (so-called T cells) either outside or inside the body, respectively. Both types are tailored to characteristics of the individual tumor tissue, thus maximizing chances of successful therapy for the individual patient. T-cell...